The following is adapted from a press release issued today by the Broad Institute.
American philanthropists and entrepreneurs Eli and Edythe Broad announced today they are investing an additional $100 million into the Broad Institute to launch a new decade of transformative work to harness recent biomedical discoveries to benefit patients.
This gift brings their total contributions to the institute to $700 million since its founding nearly a decade ago — and makes the Broads the second-largest donors ever to a university, hospital, or research institute for biomedical research.
“When we made our first investment to create the Broad Institute, we shared Eric Lander’s vision that discoveries in biomedical research held the key to beating devastating disease and improving people’s lives,” says Eli Broad, founder of The Broad Foundations. “As the Broad Institute nears its 10th anniversary, it has already made transformative discoveries, building on the successes of the Human Genome Project. Our latest investment is intended to catalyze the next decade of innovation and discovery. Our goal is to enable the Broad Institute community to continue to take bold risks, bring together the brightest minds in the field, and pursue game-changing breakthroughs that are needed to make a difference in science and medicine.”
The Broad Institute was founded in 2003 as an unprecedented model of research collaboration, bringing together scientists from across the MIT and Harvard University communities, including the Harvard-affiliated teaching hospitals, and from diverse disciplines including biology, medicine, chemistry, and computer science.
“There is no place like the Broad Institute,” Broad says. “The legacy of collaboration across disciplines coupled with transformative talent, technology, and resources will endure far beyond the next decade. Edye and I can’t wait to see what they will tackle next.”
Through collaborations that span the Broad Institute’s partner institutions and other organizations across the globe, the Broad has pioneered scientific advances aimed at developing a deeper, more precise understanding of disease biology and opening up entirely new paradigms for diagnosis and treatment. These approaches include:
Over the last decade, Broad researchers have led pioneering work in human biology that forms the cornerstone of its next decade of research. This includes the development and application of state-of-the-art genomic methods that have propelled the discovery of hundreds of genes at play in major human diseases, including common diseases like type 2 diabetes and early-onset heart disease; psychiatric diseases such as autism and schizophrenia; autoimmune diseases such as inflammatory bowel disease and rheumatoid arthritis; infectious diseases such as malaria and tuberculosis; dozens of cancers; and many others.
In the next decade, Broad researchers will apply this knowledge to develop therapeutic roadmaps for a variety of human diseases, enabling a new world of more precise and effective treatment options for patients.
“Eli and Edye are true visionaries, and I am grateful for their support of such a critical, forward-looking effort,” MIT President L. Rafael Reif says. “The Broad Institute, the scientific community, as well as society as a whole will reap the benefits of their generosity and vision for generations to come.”
“With their generous gift, the Broads are making possible an entirely new approach for understanding, diagnosing, and treating human disease,” Harvard President Drew Faust says. “We are grateful for their continued support and for our extraordinary partnership with the Broad Institute.”
The Broads’ $100 million gift is their fourth gift to the Broad Institute. In 2004, an initial $100 million investment launched the institute, and was followed a year later by a second $100 million. In 2008, the Broads pledged $400 million to endow and establish the Broad Institute as an independent nonprofit scientific research institution, making it a permanent part of the biomedical landscape. Their combined contributions make them the second-largest donors to a single organization for biomedical research.
“I’m profoundly grateful to Eli and Edye for their partnership and support,” Lander says. “Their extraordinary philanthropy is enabling innovation in science and medicine that will directly impact human health for generations to come.”
American philanthropists and entrepreneurs Eli and Edythe Broad announced today they are investing an additional $100 million into the Broad Institute to launch a new decade of transformative work to harness recent biomedical discoveries to benefit patients.
This gift brings their total contributions to the institute to $700 million since its founding nearly a decade ago — and makes the Broads the second-largest donors ever to a university, hospital, or research institute for biomedical research.
“When we made our first investment to create the Broad Institute, we shared Eric Lander’s vision that discoveries in biomedical research held the key to beating devastating disease and improving people’s lives,” says Eli Broad, founder of The Broad Foundations. “As the Broad Institute nears its 10th anniversary, it has already made transformative discoveries, building on the successes of the Human Genome Project. Our latest investment is intended to catalyze the next decade of innovation and discovery. Our goal is to enable the Broad Institute community to continue to take bold risks, bring together the brightest minds in the field, and pursue game-changing breakthroughs that are needed to make a difference in science and medicine.”
The Broad Institute was founded in 2003 as an unprecedented model of research collaboration, bringing together scientists from across the MIT and Harvard University communities, including the Harvard-affiliated teaching hospitals, and from diverse disciplines including biology, medicine, chemistry, and computer science.
“There is no place like the Broad Institute,” Broad says. “The legacy of collaboration across disciplines coupled with transformative talent, technology, and resources will endure far beyond the next decade. Edye and I can’t wait to see what they will tackle next.”
Through collaborations that span the Broad Institute’s partner institutions and other organizations across the globe, the Broad has pioneered scientific advances aimed at developing a deeper, more precise understanding of disease biology and opening up entirely new paradigms for diagnosis and treatment. These approaches include:
- discovering the genes and molecular underpinnings of major human diseases ranging from diabetes to cancer to infectious disease;
- applying this knowledge to systematically map the “wiring diagram” of cell control, revealing the key vulnerabilities that underlie disease; and
- discovering and developing diverse chemical compounds that can target those vulnerabilities.
Over the last decade, Broad researchers have led pioneering work in human biology that forms the cornerstone of its next decade of research. This includes the development and application of state-of-the-art genomic methods that have propelled the discovery of hundreds of genes at play in major human diseases, including common diseases like type 2 diabetes and early-onset heart disease; psychiatric diseases such as autism and schizophrenia; autoimmune diseases such as inflammatory bowel disease and rheumatoid arthritis; infectious diseases such as malaria and tuberculosis; dozens of cancers; and many others.
In the next decade, Broad researchers will apply this knowledge to develop therapeutic roadmaps for a variety of human diseases, enabling a new world of more precise and effective treatment options for patients.
“Eli and Edye are true visionaries, and I am grateful for their support of such a critical, forward-looking effort,” MIT President L. Rafael Reif says. “The Broad Institute, the scientific community, as well as society as a whole will reap the benefits of their generosity and vision for generations to come.”
“With their generous gift, the Broads are making possible an entirely new approach for understanding, diagnosing, and treating human disease,” Harvard President Drew Faust says. “We are grateful for their continued support and for our extraordinary partnership with the Broad Institute.”
The Broads’ $100 million gift is their fourth gift to the Broad Institute. In 2004, an initial $100 million investment launched the institute, and was followed a year later by a second $100 million. In 2008, the Broads pledged $400 million to endow and establish the Broad Institute as an independent nonprofit scientific research institution, making it a permanent part of the biomedical landscape. Their combined contributions make them the second-largest donors to a single organization for biomedical research.
“I’m profoundly grateful to Eli and Edye for their partnership and support,” Lander says. “Their extraordinary philanthropy is enabling innovation in science and medicine that will directly impact human health for generations to come.”
